Lucile Plumet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lucile Plumet has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Virginie Molle
VBIC, INSERM U1047, University of Montpellier, 34095 Montpellier, France
11 shared publications - Jean-Philippe Lavigne
Virulence Bactérienne et Infections Chroniques, INSERM U1047, Univ Montpellier, Service de Microbiologie et Hygiène Hospitalière, Centre National de Reference des brucelloses, CHU Nîmes, Nîmes, France
8 shared publications Albert Sotto
Department of Infectious Diseases, VBIC, INSERM U1047, University of Montpellier, CHU Nîmes
6 shared publicationsChloé Magnan
VBIC, INSERM U1047, Department of Microbiology and Hospital Hygiene, University of Montpellier, CHU Nîmes
5 shared publicationsDenis Costechareyre
Greenphage, Cap Alpha
4 shared publicationsKarima Kissa
VBIC, INSERM U1047, University of Montpellier, Montpellier, France
4 shared publications
Latest Publications
- 6 November 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
La phagothérapie contre les staphylocoques responsables des infections du pied diabétique
Les infections du pied diabétique représentent une complication fréquente du diabète,associée à une morbidité importante et à des traitements souvent longs et peu efficaces,notamment en raison de la présence de biofilms et de souches bactériennes multirésistantes. Staphylococcus aureus et certains staphylocoques à coagulase négative (SCN) y occupent une place centrale. Face aux limites croissantes des antibiothérapies conventionnelles, la phagothérapie, qui repose sur l’utilisation de bactériophages ciblant spécifiquement les bactéries, apparaît comme une alternative prometteuse. Cette thèse a pour objectif d’explorer le potentiel thérapeutique de phages dirigés contre des staphylocoques isolés d’infections du pied diabétique, à travers une approche intégrée combinant isolement, évaluation in vivo et adaptation évolutive.Dans un premier temps, six phages lytiques ont été isolés à partir d’échantillons environnementaux, caractérisés génétiquement et testés sur un panel de souches cliniques de S. aureus et de SCN. Certains ont montré une activité antibiofilm et une efficacité sur des souches multirésistantes aux antibiotiques. Un modèle in vivo basé sur l’embryon de poisson zèbre a ensuite été mis au point, permettant une visualisation en temps réel et une quantification précise de l’e[et thérapeutique via une infection localisée par des souches fluorescentes. Le traitement par phage a significativement amélioré la survie des embryons infectés, tout en montrant une excellente tolérance. Enfin, une stratégie d’évolution dirigée par phage training a permis d’élargir le spectre d’action d’un des phages sur des souches initialement résistantes aux phages. Ce travail propose une approche de phagothérapie personnalisée, capable de s’adapter aux souches bactériennes spécifiques du patient. Dans l’ensemble, ces travaux illustrent la pertinence d’une approche intégrée pour le développement de phages thérapeutiques ciblant les staphylocoques impliqués dans les infections du pied diabétique. De l’isolement à l’évolution dirigée, en passant par l’évaluation in vivo, ces résultats offrent une base méthodologique solide pour explorer des stratégies thérapeutiques innovantes face à l’antibiorésistance.
- 6 November 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
La phagothérapie contre les staphylocoques responsables des infections du pied diabétique
Les infections du pied diabétique représentent une complication fréquente du diabète,associée à une morbidité importante et à des traitements souvent longs et peu efficaces,notamment en raison de la présence de biofilms et de souches bactériennes multirésistantes. Staphylococcus aureus et certains staphylocoques à coagulase négative (SCN) y occupent une place centrale. Face aux limites croissantes des antibiothérapies conventionnelles, la phagothérapie, qui repose sur l’utilisation de bactériophages ciblant spécifiquement les bactéries, apparaît comme une alternative prometteuse. Cette thèse a pour objectif d’explorer le potentiel thérapeutique de phages dirigés contre des staphylocoques isolés d’infections du pied diabétique, à travers une approche intégrée combinant isolement, évaluation in vivo et adaptation évolutive.Dans un premier temps, six phages lytiques ont été isolés à partir d’échantillons environnementaux, caractérisés génétiquement et testés sur un panel de souches cliniques de S. aureus et de SCN. Certains ont montré une activité antibiofilm et une efficacité sur des souches multirésistantes aux antibiotiques. Un modèle in vivo basé sur l’embryon de poisson zèbre a ensuite été mis au point, permettant une visualisation en temps réel et une quantification précise de l’e[et thérapeutique via une infection localisée par des souches fluorescentes. Le traitement par phage a significativement amélioré la survie des embryons infectés, tout en montrant une excellente tolérance. Enfin, une stratégie d’évolution dirigée par phage training a permis d’élargir le spectre d’action d’un des phages sur des souches initialement résistantes aux phages. Ce travail propose une approche de phagothérapie personnalisée, capable de s’adapter aux souches bactériennes spécifiques du patient. Dans l’ensemble, ces travaux illustrent la pertinence d’une approche intégrée pour le développement de phages thérapeutiques ciblant les staphylocoques impliqués dans les infections du pied diabétique. De l’isolement à l’évolution dirigée, en passant par l’évaluation in vivo, ces résultats offrent une base méthodologique solide pour explorer des stratégies thérapeutiques innovantes face à l’antibiorésistance.
- Open Access
- 7 October 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (10)
Training a phage to expand its host range: directed evolution against Staphylococcus aureus from diabetic foot infections
Diabetic foot infections (DFIs) are a major complication of diabetes frequently involving multidrug-resistant Staphylococcus aureus . Their persistence and therapeutic complexity underscore the urgent need for alternatives to conventional antibiotics. Phage therapy offers a promising solution, though its clinical application is often limited by the narrow host range of individual phages. Here, SAVM02, a recently characterized staphylococcal Kayvirus , was trained using directed evolution against DFI isolates. After 20 iterative passages on a mixed panel of susceptible and non-susceptible S. aureus strains, the trained phage pool (SAVM02-P20) displayed markedly enhanced activity, infecting approximately 77% of tested S. aureus isolates and showing partial cross-species activity against coagulase-negative staphylococci. Improved infectivity was linked to increased replication efficiency rather than adsorption. Genomic and phylogenetic analyses further suggested recurrent adaptive changes and preferential host-range expansion within genetically related lineages. In vivo testing in a zebrafish embryo model confirmed therapeutic efficacy against a fully susceptible strain but revealed no survival benefit against an initially poorly permissive isolate, highlighting the gap between in vitro adaptation and in vivo efficacy. These findings demonstrate both the potential and the limitations of phage training to expand therapeutic coverage and emphasize the need to integrate evolutionary approaches with physiologically relevant models to optimize phage therapy for chronic infections, such as DFIs.
- 7 October 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (10)
Open AccessTraining a phage to expand its host range: directed evolution against Staphylococcus aureus from diabetic foot infections
Diabetic foot infections (DFIs) are a major complication of diabetes frequently involving multidrug-resistant Staphylococcus aureus . Their persistence and therapeutic complexity underscore the urgent need for alternatives to conventional antibiotics. Phage therapy offers a promising solution, though its clinical application is often limited by the narrow host range of individual phages. Here, SAVM02, a recently characterized staphylococcal Kayvirus , was trained using directed evolution against DFI isolates. After 20 iterative passages on a mixed panel of susceptible and non-susceptible S. aureus strains, the trained phage pool (SAVM02-P20) displayed markedly enhanced activity, infecting approximately 77% of tested S. aureus isolates and showing partial cross-species activity against coagulase-negative staphylococci. Improved infectivity was linked to increased replication efficiency rather than adsorption. Genomic and phylogenetic analyses further suggested recurrent adaptive changes and preferential host-range expansion within genetically related lineages. In vivo testing in a zebrafish embryo model confirmed therapeutic efficacy against a fully susceptible strain but revealed no survival benefit against an initially poorly permissive isolate, highlighting the gap between in vitro adaptation and in vivo efficacy. These findings demonstrate both the potential and the limitations of phage training to expand therapeutic coverage and emphasize the need to integrate evolutionary approaches with physiologically relevant models to optimize phage therapy for chronic infections, such as DFIs.
- Open Access
- 6 October 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (10)
First characterization of Staphylococcus felis in diabetic foot osteomyelitis: from intracellular persistence to phage treatment
Staphylococcus felis is a coagulase-negative Staphylococcus (CoNS) primarily associated with the feline microbiota and only rarely reported in human disease. Here, we report its implication in diabetic foot osteomyelitis, and provide the first comprehensive characterization of its pathogenic potential. Two isolates (NSF001 and NSF002), recovered 5 months apart from bone biopsies of the same patient, were analyzed for growth kinetics, biofilm formation, and intracellular persistence in macrophages and osteoblasts. Both isolates proliferated efficiently, produced robust biofilm, and persisted within host cells, most markedly in osteoblasts. In a zebrafish embryo infection model, both isolates caused significant mortality, confirming their pathogenic potential in vivo . Whole-genome sequencing revealed conserved virulence determinants, a narrow resistome, and strain-specific genomic variations affecting genes involved in virulence regulation, phage defense, and iron acquisition. The lytic phage SAVM02, previously characterized for activity against other Staphylococcus species, effectively inhibited S. felis growth in vitro and conferred protection in vivo against lethal infection. Notably, the two sequential isolates differed in their in vivo virulence and phage susceptibility, paralleling these within-host microevolutionary changes and illustrating bacterial adaptation during chronic infection. Altogether, this study establishes S. felis as a CoNS capable of intracellular persistence, biofilm formation, and in vivo virulence in chronic human infection. Our findings also highlight the therapeutic potential of lytic phages against virulent CoNS species and support further investigation of phage therapy for chronic staphylococcal infections. IMPORTANCE: Coagulase-negative staphylococci (CoNS) are increasingly recognized as genuine agents of chronic infection, yet the pathogenic capacity of most individual species remains undefined. Staphylococcus felis , a commensal of cats only exceptionally reported in humans, had never been implicated in a chronic human infection. Here, we describe two sequential S. felis isolates recovered from bone biopsies of a patient with diabetic foot osteomyelitis and show that this species combines biofilm formation, intracellular persistence in macrophages and osteoblasts, and lethality in a zebrafish embryo model. Whole-genome comparison of the two isolates uncovered microevolutionary changes, most notably in iron-acquisition and genome-defense loci, that paralleled differences in virulence and phage susceptibility. These findings extend the list of CoNS capable of causing invasive human disease and provide a rationale for lytic phage therapy against emerging, difficult-to-treat staphylococcal pathogens.
- 6 October 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (10)
Open AccessFirst characterization of Staphylococcus felis in diabetic foot osteomyelitis: from intracellular persistence to phage treatment
Staphylococcus felis is a coagulase-negative Staphylococcus (CoNS) primarily associated with the feline microbiota and only rarely reported in human disease. Here, we report its implication in diabetic foot osteomyelitis, and provide the first comprehensive characterization of its pathogenic potential. Two isolates (NSF001 and NSF002), recovered 5 months apart from bone biopsies of the same patient, were analyzed for growth kinetics, biofilm formation, and intracellular persistence in macrophages and osteoblasts. Both isolates proliferated efficiently, produced robust biofilm, and persisted within host cells, most markedly in osteoblasts. In a zebrafish embryo infection model, both isolates caused significant mortality, confirming their pathogenic potential in vivo . Whole-genome sequencing revealed conserved virulence determinants, a narrow resistome, and strain-specific genomic variations affecting genes involved in virulence regulation, phage defense, and iron acquisition. The lytic phage SAVM02, previously characterized for activity against other Staphylococcus species, effectively inhibited S. felis growth in vitro and conferred protection in vivo against lethal infection. Notably, the two sequential isolates differed in their in vivo virulence and phage susceptibility, paralleling these within-host microevolutionary changes and illustrating bacterial adaptation during chronic infection. Altogether, this study establishes S. felis as a CoNS capable of intracellular persistence, biofilm formation, and in vivo virulence in chronic human infection. Our findings also highlight the therapeutic potential of lytic phages against virulent CoNS species and support further investigation of phage therapy for chronic staphylococcal infections. IMPORTANCE: Coagulase-negative staphylococci (CoNS) are increasingly recognized as genuine agents of chronic infection, yet the pathogenic capacity of most individual species remains undefined. Staphylococcus felis , a commensal of cats only exceptionally reported in humans, had never been implicated in a chronic human infection. Here, we describe two sequential S. felis isolates recovered from bone biopsies of a patient with diabetic foot osteomyelitis and show that this species combines biofilm formation, intracellular persistence in macrophages and osteoblasts, and lethality in a zebrafish embryo model. Whole-genome comparison of the two isolates uncovered microevolutionary changes, most notably in iron-acquisition and genome-defense loci, that paralleled differences in virulence and phage susceptibility. These findings extend the list of CoNS capable of causing invasive human disease and provide a rationale for lytic phage therapy against emerging, difficult-to-treat staphylococcal pathogens.
- 11 December 2025
- Published by American Society for Microbiology in Clinical Microbiology Reviews
- Vol. 38 (4) , e0012125
A narrative review of coagulase-negative staphylococci in diabetic foot infections
SUMMARY: Coagulase-negative staphylococci (CoNS) are a group of bacteria commonly found on human skin and mucous membranes. Traditionally regarded as low-virulence microorganisms, they have gained recognition as significant pathogens in healthcare-associated infections, particularly among immunocompromised individuals and patients with indwelling medical devices. In diabetic foot infections (DFIs), CoNS can play a substantial role, particularly following previous antibiotic treatments or in the presence of indwelling devices. DFIs are usually polymicrobial, involving a mixture of aerobic and anaerobic bacteria. Although Staphylococcus aureus is recognized as the major pathogen, especially in Western countries, CoNS are increasingly emerging as significant pathogens in DFIs, including osteomyelitis. Their presence may complicate treatment by increasing the microbial burden and harboring antibiotic resistance mechanisms. The treatment of DFIs involving CoNS often requires a combination of antibiotics targeting both gram-positive and gram-negative bacteria, selected according to the severity of the infection and results of antibiotic susceptibility testing. This review aims to highlight the growing importance of CoNS in DFIs, discussing their pathogenic mechanisms, clinical implications, and the necessity for healthcare providers to consider their involvement in order to ensure effective treatment and successful patient outcomes. This narrative review aims to underscore the growing clinical relevance of CoNS in DFIs by exploring their pathogenic mechanisms, diagnostic challenges, and therapeutic implications. It emphasizes the need for clinicians to recognize CoNS as potential pathogens rather than mere contaminants and highlights the ongoing difficulty in distinguishing true infection from colonization. This distinction is critical for accurate diagnosis, appropriate antimicrobial stewardship, and the development of improved treatment strategies.
- 11 December 2025
- Published by American Society for Microbiology in Clinical Microbiology Reviews
- Vol. 38 (4) , e0012125
A narrative review of coagulase-negative staphylococci in diabetic foot infections
SUMMARY: Coagulase-negative staphylococci (CoNS) are a group of bacteria commonly found on human skin and mucous membranes. Traditionally regarded as low-virulence microorganisms, they have gained recognition as significant pathogens in healthcare-associated infections, particularly among immunocompromised individuals and patients with indwelling medical devices. In diabetic foot infections (DFIs), CoNS can play a substantial role, particularly following previous antibiotic treatments or in the presence of indwelling devices. DFIs are usually polymicrobial, involving a mixture of aerobic and anaerobic bacteria. Although Staphylococcus aureus is recognized as the major pathogen, especially in Western countries, CoNS are increasingly emerging as significant pathogens in DFIs, including osteomyelitis. Their presence may complicate treatment by increasing the microbial burden and harboring antibiotic resistance mechanisms. The treatment of DFIs involving CoNS often requires a combination of antibiotics targeting both gram-positive and gram-negative bacteria, selected according to the severity of the infection and results of antibiotic susceptibility testing. This review aims to highlight the growing importance of CoNS in DFIs, discussing their pathogenic mechanisms, clinical implications, and the necessity for healthcare providers to consider their involvement in order to ensure effective treatment and successful patient outcomes. This narrative review aims to underscore the growing clinical relevance of CoNS in DFIs by exploring their pathogenic mechanisms, diagnostic challenges, and therapeutic implications. It emphasizes the need for clinicians to recognize CoNS as potential pathogens rather than mere contaminants and highlights the ongoing difficulty in distinguishing true infection from colonization. This distinction is critical for accurate diagnosis, appropriate antimicrobial stewardship, and the development of improved treatment strategies.
- Open Access
- 17 June 2025
- Published by American Society for Microbiology in Journal of Virology
- Vol. 99 (6) , e0045825
Phage therapy: a promising approach for Staphylococcus aureus diabetic foot infections
Diabetic foot infections (DFIs), predominantly caused by Staphylococcus aureus , pose a significant healthcare challenge with severe consequences, including amputation. Phage therapy, which utilizes bacteriophages to specifically target bacterial pathogens, has emerged as a promising alternative to conventional antibiotic treatments. This review evaluates the efficacy of phage therapy as a complementary treatment for DFIs caused by S. aureus , synthesizing evidence from preclinical and clinical studies while addressing the limitations and challenges associated with current research. The analysis highlights promising results from diabetic animal models, demonstrating effective bacterial load reduction and improved wound healing. Clinical case reports and series further underline significant improvements in infection management and ulcer healing, with no major adverse effects reported. Ongoing clinical trials are also discussed, offering insights into the study parameters evaluating phage therapy potential efficacy and safety for S. aureus -related DFIs. While the collected data highlight the potential of phage therapy as a valuable complement to traditional antibiotic treatments, particularly in managing antibiotic-resistant infections, further research is essential to address existing limitations, including gaps in long-term efficacy data and challenges in standardization. With continued investigation, phage therapy holds significant potential to alleviate the healthcare burden of DFIs and improve patient outcomes.
- 17 June 2025
- Published by American Society for Microbiology in Journal of Virology
- Vol. 99 (6) , e0045825
Open AccessPhage therapy: a promising approach for Staphylococcus aureus diabetic foot infections
Diabetic foot infections (DFIs), predominantly caused by Staphylococcus aureus , pose a significant healthcare challenge with severe consequences, including amputation. Phage therapy, which utilizes bacteriophages to specifically target bacterial pathogens, has emerged as a promising alternative to conventional antibiotic treatments. This review evaluates the efficacy of phage therapy as a complementary treatment for DFIs caused by S. aureus , synthesizing evidence from preclinical and clinical studies while addressing the limitations and challenges associated with current research. The analysis highlights promising results from diabetic animal models, demonstrating effective bacterial load reduction and improved wound healing. Clinical case reports and series further underline significant improvements in infection management and ulcer healing, with no major adverse effects reported. Ongoing clinical trials are also discussed, offering insights into the study parameters evaluating phage therapy potential efficacy and safety for S. aureus -related DFIs. While the collected data highlight the potential of phage therapy as a valuable complement to traditional antibiotic treatments, particularly in managing antibiotic-resistant infections, further research is essential to address existing limitations, including gaps in long-term efficacy data and challenges in standardization. With continued investigation, phage therapy holds significant potential to alleviate the healthcare burden of DFIs and improve patient outcomes.
- Open Access
The Staphylococcus aureus prophage-encoded SSBP attenuates virulence and enhances IL-6-mediated macrophage clearance
Pathogens often manipulate host immune responses to promote infection. Here, we describe a novel mechanism by which a secreted prophage-encoded single-stranded DNA-binding protein (SSBP) attenuates Staphylococcus aureus virulence while enhancing host immune defenses. SSBP, encoded by the ROSA-like prophage in a colonizing, reduced-virulence strain of S. aureus (NSA1385), significantly increases bacterial susceptibility to macrophage-mediated killing in vitro and reduces pathogenicity in a zebrafish infection model. Treatment with purified recombinant SSBP decreases bacterial survival within macrophages and demonstrates therapeutic potential. Notably, SSBP activates macrophages via interleukin-6 (IL-6), a pro-inflammatory cytokine that promotes bacterial clearance and macrophage activation. These findings uncover an unexpected prophage-derived mechanism in a colonizing S. aureus strain that attenuates virulence while stimulating host immunity, offering promising avenues for anti-infective therapies and immunomodulatory strategies.
Open AccessThe Staphylococcus aureus prophage-encoded SSBP attenuates virulence and enhances IL-6-mediated macrophage clearance
Pathogens often manipulate host immune responses to promote infection. Here, we describe a novel mechanism by which a secreted prophage-encoded single-stranded DNA-binding protein (SSBP) attenuates Staphylococcus aureus virulence while enhancing host immune defenses. SSBP, encoded by the ROSA-like prophage in a colonizing, reduced-virulence strain of S. aureus (NSA1385), significantly increases bacterial susceptibility to macrophage-mediated killing in vitro and reduces pathogenicity in a zebrafish infection model. Treatment with purified recombinant SSBP decreases bacterial survival within macrophages and demonstrates therapeutic potential. Notably, SSBP activates macrophages via interleukin-6 (IL-6), a pro-inflammatory cytokine that promotes bacterial clearance and macrophage activation. These findings uncover an unexpected prophage-derived mechanism in a colonizing S. aureus strain that attenuates virulence while stimulating host immunity, offering promising avenues for anti-infective therapies and immunomodulatory strategies.
- 8 October 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (10) , e0082924
Zebrafish as an effective model for evaluating phage therapy in bacterial infections: a promising strategy against human pathogens
The escalating prevalence of antibiotic-resistant bacterial infections necessitates urgent alternative therapeutic strategies. Phage therapy, which employs bacteriophages to specifically target pathogenic bacteria, emerges as a promising solution. This review examines the efficacy of phage therapy in zebrafish models, both embryos and adults, which are proven and reliable for simulating human infectious diseases. We synthesize findings from recent studies that utilized these models to assess phage treatments against various bacterial pathogens, including Enterococcus faecalis , Pseudomonas aeruginosa , Mycobacterium abscessus , Staphylococcus aureus , Klebsiella pneumoniae , Acinetobacter baumannii , and Escherichia coli . Methods of phage administration, such as circulation injection and bath immersion, are detailed alongside evaluations of survival rates and bacterial load reductions. Notably, combination therapies of phages with antibiotics show enhanced efficacy, as evidenced by improved survival rates and synergistic effects in reducing bacterial loads. We also discuss the transition from zebrafish embryos to adult models, emphasizing the increased complexity of immune responses. This review highlights the valuable contribution of the zebrafish model to advancing phage therapy research, particularly in the face of rising antibiotic resistance and the urgent need for alternative treatments.
- 8 October 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (10) , e0082924
Zebrafish as an effective model for evaluating phage therapy in bacterial infections: a promising strategy against human pathogens
The escalating prevalence of antibiotic-resistant bacterial infections necessitates urgent alternative therapeutic strategies. Phage therapy, which employs bacteriophages to specifically target pathogenic bacteria, emerges as a promising solution. This review examines the efficacy of phage therapy in zebrafish models, both embryos and adults, which are proven and reliable for simulating human infectious diseases. We synthesize findings from recent studies that utilized these models to assess phage treatments against various bacterial pathogens, including Enterococcus faecalis , Pseudomonas aeruginosa , Mycobacterium abscessus , Staphylococcus aureus , Klebsiella pneumoniae , Acinetobacter baumannii , and Escherichia coli . Methods of phage administration, such as circulation injection and bath immersion, are detailed alongside evaluations of survival rates and bacterial load reductions. Notably, combination therapies of phages with antibiotics show enhanced efficacy, as evidenced by improved survival rates and synergistic effects in reducing bacterial loads. We also discuss the transition from zebrafish embryos to adult models, emphasizing the increased complexity of immune responses. This review highlights the valuable contribution of the zebrafish model to advancing phage therapy research, particularly in the face of rising antibiotic resistance and the urgent need for alternative treatments.
- 9 July 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (7) , e0056124
The zebrafish embryo model: unveiling its potential for investigating phage therapy against methicillin-resistant Staphylococcus aureus infection
Staphylococcus aureus is a pathogenic bacterium responsible for a broad spectrum of infections, including cutaneous, respiratory, osteoarticular, and systemic infections. It poses a significant clinical challenge due to its ability to develop antibiotic resistance. This resistance limits therapeutic options, increases the risk of severe complications, and underscores the urgent need for new strategies to address this threat, including the investigation of treatments complementary to antibiotics. The evaluation of novel antimicrobial agents often employs animal models, with the zebrafish embryo model being particularly interesting for studying host-pathogen interactions, establishing itself as a crucial tool in this field. For the first time, this study presents a zebrafish embryo model for the in vivo assessment of bacteriophage efficacy against S. aureus infection. A localized infection was induced by microinjecting either methicillin-resistant S. aureus (MRSA) or methicillin-susceptible S. aureus (MSSA). Subsequent treatments involved administering either bacteriophage, vancomycin (the reference antibiotic for MRSA), or a combination of both via the same route to explore potential synergistic effects. Our findings indicate that the bacteriophage was as effective as vancomycin in enhancing survival rates, whether used alone or in combination. Moreover, bacteriophage treatment appears to be even more effective in reducing the bacterial load in S. aureus -infected embryos post-treatment than the antibiotic. Our study validates the use of the zebrafish embryo model and highlights its potential as a valuable tool in assessing bacteriophage efficacy treatments in vivo .
- 9 July 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (7) , e0056124
The zebrafish embryo model: unveiling its potential for investigating phage therapy against methicillin-resistant Staphylococcus aureus infection
Staphylococcus aureus is a pathogenic bacterium responsible for a broad spectrum of infections, including cutaneous, respiratory, osteoarticular, and systemic infections. It poses a significant clinical challenge due to its ability to develop antibiotic resistance. This resistance limits therapeutic options, increases the risk of severe complications, and underscores the urgent need for new strategies to address this threat, including the investigation of treatments complementary to antibiotics. The evaluation of novel antimicrobial agents often employs animal models, with the zebrafish embryo model being particularly interesting for studying host-pathogen interactions, establishing itself as a crucial tool in this field. For the first time, this study presents a zebrafish embryo model for the in vivo assessment of bacteriophage efficacy against S. aureus infection. A localized infection was induced by microinjecting either methicillin-resistant S. aureus (MRSA) or methicillin-susceptible S. aureus (MSSA). Subsequent treatments involved administering either bacteriophage, vancomycin (the reference antibiotic for MRSA), or a combination of both via the same route to explore potential synergistic effects. Our findings indicate that the bacteriophage was as effective as vancomycin in enhancing survival rates, whether used alone or in combination. Moreover, bacteriophage treatment appears to be even more effective in reducing the bacterial load in S. aureus -infected embryos post-treatment than the antibiotic. Our study validates the use of the zebrafish embryo model and highlights its potential as a valuable tool in assessing bacteriophage efficacy treatments in vivo .
- Open Access
Isolation and Characterization of New Bacteriophages against Staphylococcal Clinical Isolates from Diabetic Foot Ulcers
Staphylococcus sp. is the most common bacterial genus in infections related to diabetic foot ulcers (DFUs). The emergence of multidrug-resistant bacteria places a serious burden on public health systems. Phage therapy is an alternative treatment to antibiotics, overcoming the issue of antibiotic resistance. In this study, six phages (SAVM01 to SAVM06) were isolated from effluents and were used against a panel of staphylococcal clinical samples isolated from DFUs. A genomic analysis revealed that the phages belonged to the Herelleviridae family, with sequences similar to those of the Kayvirus genus. No lysogeny-associated genes, known virulence or drug resistance genes were identified in the phage genomes. The phages displayed a strong lytic and antibiofilm activity against DFU clinical isolates, as well as against opportunistic pathogenic coagulase-negative staphylococci. The results presented here suggest that these phages could be effective biocontrol agents against staphylococcal clinical isolates from DFUs.
Open AccessIsolation and Characterization of New Bacteriophages against Staphylococcal Clinical Isolates from Diabetic Foot Ulcers
Staphylococcus sp. is the most common bacterial genus in infections related to diabetic foot ulcers (DFUs). The emergence of multidrug-resistant bacteria places a serious burden on public health systems. Phage therapy is an alternative treatment to antibiotics, overcoming the issue of antibiotic resistance. In this study, six phages (SAVM01 to SAVM06) were isolated from effluents and were used against a panel of staphylococcal clinical samples isolated from DFUs. A genomic analysis revealed that the phages belonged to the Herelleviridae family, with sequences similar to those of the Kayvirus genus. No lysogeny-associated genes, known virulence or drug resistance genes were identified in the phage genomes. The phages displayed a strong lytic and antibiofilm activity against DFU clinical isolates, as well as against opportunistic pathogenic coagulase-negative staphylococci. The results presented here suggest that these phages could be effective biocontrol agents against staphylococcal clinical isolates from DFUs.
- 21 June 2023
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 228 (12) , 1800-1804
The ROSA-Like Prophage Colonizing Staphylococcus aureus Promotes Intracellular Survival, Biofilm Formation, and Virulence in a Chronic Wound Environment
The transition from colonization to invasion is critical in diabetic foot ulcer (DFU). Staphylococcus aureus can colonize DFU, or invade the underlying tissues, causing serious infections. The ROSA-like prophage has previously been implicated in strain colonization characteristics of S aureus isolates in uninfected ulcers. In this study, we investigated this prophage in the S aureus-colonizing strain using an in vitro chronic wound medium mimicking the chronic wound environment. Chronic wound medium reduced bacterial growth and increased biofilm formation and virulence in a zebrafish model. The ROSA-like prophage promoted intracellular survival of S aureus-colonizing strain in macrophages, keratinocytes, and osteoblasts.
- 21 June 2023
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 228 (12) , 1800-1804
The ROSA-Like Prophage Colonizing Staphylococcus aureus Promotes Intracellular Survival, Biofilm Formation, and Virulence in a Chronic Wound Environment
The transition from colonization to invasion is critical in diabetic foot ulcer (DFU). Staphylococcus aureus can colonize DFU, or invade the underlying tissues, causing serious infections. The ROSA-like prophage has previously been implicated in strain colonization characteristics of S aureus isolates in uninfected ulcers. In this study, we investigated this prophage in the S aureus-colonizing strain using an in vitro chronic wound medium mimicking the chronic wound environment. Chronic wound medium reduced bacterial growth and increased biofilm formation and virulence in a zebrafish model. The ROSA-like prophage promoted intracellular survival of S aureus-colonizing strain in macrophages, keratinocytes, and osteoblasts.